In the spring of 2003, Hovione opened a small-scale production facility in East Windsor, N.J. As its name implies, the $20 million Technology Transfer Center was intended as a place to develop customers' molecules before moving them to headquarters in Loures, Portugal, for scale-up. Given Hovione's target market of small to midsized drug companies, TTC was meant to boost business with U.S. biotech firms.